Literature DB >> 12779080

Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

Nicole Concin1, Christa Zeillinger, Dan Tong, Margit Stimpfl, Margit König, Dieter Printz, Felix Stonek, Christian Schneeberger, Lukas Hefler, Christian Kainz, Sepp Leodolter, Oskar A Haas, Robert Zeillinger.   

Abstract

We analyzed the p53 mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53 with fluorescence in situ hybridization (FISH). A functional yeast assay (FASAY) was used to screen for inactivating mutations. Positive results were subsequently verified by DNA sequencing. Finally, we assessed the mRNA expression with a competitive reverse transcription-polymerase chain reaction (RT-PCR) assay and the protein expression with immunocytochemical staining, western blot, and quantitative flow cytometry. The DNA content of the cell lines ranged from 0.85 to 2.58. Nine cell lines had concordant copy numbers (between two and four) of p53 and cen17, whereas 12 had more, and three less cen17 than p53 copies. The FASAY was successful in all but one cell line and revealed the presence of mutated alleles in 16 of them, 13 cell lines expressed only the mutated, and three both the mutated and the wild-type alleles. The mutations were comprised of 11 missense, two nonsense, and three frameshift mutations. Immunocytochemical staining, western blot and quantitative flow cytometry yielded comparable p53 protein expression results. However, both the mRNA and the protein expression levels varied considerably in the different cell lines and no consistent pattern with regard to the respective p53 mutational status became evident. The results obtained in these breast carcinoma cell lines indicate that no clear-cut linear relationship exists between the p53 mutational status and the extent of its respective mRNA and protein expression. Therefore, direct DNA analyses and functional assays remain the only methods for the reliable detection of p53 mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12779080     DOI: 10.1023/a:1023351717408

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Authors:  Marie-Jo Halaby; Benjamin R E Harris; W Keith Miskimins; Margot P Cleary; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

2.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

4.  Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells.

Authors:  Jeanette Nilsson; Gunnar Bjursell; Marie Kannius-Janson
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

5.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

6.  Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.

Authors:  Uma Chandrachud; Susannah Gal
Journal:  Technol Cancer Res Treat       Date:  2009-12

7.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.

Authors:  Lu Chen; Julie Ann Mayer; Tibor I Krisko; Corey W Speers; Tao Wang; Susan G Hilsenbeck; Powel H Brown
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

8.  Mitochondrial dysfunction in human breast cancer cells and their transmitochondrial cybrids.

Authors:  Yewei Ma; Ren-Kui Bai; Robert Trieu; Lee-Jun C Wong
Journal:  Biochim Biophys Acta       Date:  2009-08-04

9.  Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.

Authors:  Mª Jesús Núñez-Iglesias; Silvia Novio; Carlota García; Mª Elena Pérez-Muñuzuri; María-Carmen Martínez; José-Luis Santiago; Susana Boso; Pilar Gago; Manuel Freire-Garabal
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

10.  Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.

Authors:  Joanne M Munck; Michael A Batey; Yan Zhao; Helen Jenkins; Caroline J Richardson; Celine Cano; Michele Tavecchio; Jody Barbeau; Julia Bardos; Liam Cornell; Roger J Griffin; Keith Menear; Andrew Slade; Pia Thommes; Niall M B Martin; David R Newell; Graeme C M Smith; Nicola J Curtin
Journal:  Mol Cancer Ther       Date:  2012-05-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.